Ose (OSE) | Stock Overview & Key Data
Ose Immunotherapeutics S.A. | Small-cap | Healthcare
Ose Immunotherapeutics S.A. | Small-cap | Healthcare
Ose Performance Comparison
Stock Range
Today's Range
Low: €5.28
High: €5.45
on July 18, 2025
52 Week Range
Low: €4.42
High: €11.58
on April 7, 2025
on November 4, 2024
All-Time High: €15.80 on February 22, 2021
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€120.5M
EPS
1.46
P/E Ratio (TTM)
3.61
Forward P/E
4.39
P/B Ratio
1.81
PEG Ratio
4.39
Div. Yield
N/A
ROE
86.29%
Beta
0.560
Debt to Equity
72.30
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-2,272.16%
Profit Margin
44.88%
Returns and Earnings
Return on Assets (TTM)
26.54%
Return on Equity (TTM)
86.29%
EBITDA
€34.6M
Net Income (TTM)
€37.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€3.81
Quarterly Revenue Growth (YoY)
-0.80%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ose OSE | 120.48M Small-cap | 4.93% | 4.52% | -5.84% | -18.78% | -29.35% | -19.03% | -19.27% | -9.83% |
| Medincell S.A MEDCL | 557.56M Mid-cap | -0.25% | -2.79% | 10.57% | -1.36% | -8.78% | 4.03% | 214.96% | 103.05% |
| Abivax SA ABVX | 547.13M Mid-cap | 21.24% | 62.95% | 60.52% | 37.92% | 18.41% | -25.95% | 2.86% | -60.64% |
| Innate Pharma S.A IPH | 145.62M Small-cap | 14.67% | 3.61% | 0.00% | -0.58% | -8.99% | -16.10% | -41.69% | -68.61% |
| Sensorion SA ALSEN | 106.99M Small-cap | 6.45% | -13.16% | 94.12% | -50.00% | -48.44% | -50.75% | -19.51% | -70.54% |
| Transgene S.A TNG | 110.78M Small-cap | -1.27% | -16.13% | 30.00% | 11.43% | 14.71% | -30.36% | -66.67% | -49.02% |
Ownership & Short Interest
Insider Ownership
26.34%
Institutional Ownership
2.86%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
54K
Average 90-Day Volume
91K
Ose Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ose would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is OSE's 52-week high and low?
- In the last 52 weeks, Ose reached a high of €11.58 (on November 4, 2024) and a low of €4.42 (on April 7, 2025).
- What is the market cap and P/E ratio for OSE?
- Curious about Ose's size and valuation? Its market capitalization stands at 120.48M. When it comes to valuation, the P/E ratio (trailing twelve months) is 3.61, and the forward P/E (looking ahead) is 4.39.
- Does OSE pay dividends? If so, what's the yield?
- As for dividends, Ose isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ose's main competitors or similar companies to consider before investing?
When looking at Ose, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Medincell S.A
MEDCL557.56M Healthcare Biotechnology 4.03% 214.96% Abivax SA
ABVX547.13M Healthcare Biotechnology -25.95% 2.86% Innate Pharma S.A
IPH145.62M Healthcare Biotechnology -16.10% -41.69% Sensorion SA
ALSEN106.99M Healthcare Biotechnology -50.75% -19.51% Transgene S.A
TNG110.78M Healthcare Biotechnology -30.36% -66.67% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ose Immunotherapeutics S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Ose's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 86.29%, the Debt to Equity ratio from the most recent quarter is 72.30, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for OSE?
- Looking at Ose's growth, its revenue over the trailing twelve months (TTM) was €83M. Compared to the same quarter last year (YoY), quarterly revenue grew by -0.80%, and quarterly earnings saw a YoY growth of N/A.
- How much of OSE stock is held by insiders and institutions?
- Wondering who owns Ose stock? Company insiders (like executives and directors) hold about 26.34% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.86%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.